Walgreens Boots Alliance Inc

Walgreens Boots Alliance — Q1 2024 Earnings Presentation

33 slides from Walgreens Boots Alliance's earnings presentation, Jan 4, 2024

  1. Slide 1: First Quarter Fiscal 2024 Results

    First Quarter Fiscal 2024 Results January 4, 2024 © 2024 Walgreens Boots Alliance, Inc. All rights reserved.

  2. Slide 2: Safe Harbor and Non-GAAP

    Safe Harbor and Non-GAAP Cautionary Note Regarding Forward-Looking Statements: All statements in this presentation that are not historical are forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These include, without limitat

  3. Slide 3: Executing on our goals in a challenging environment

    Executing on our goals in a challenging environment • 1Q results met expectations − Execution and cost discipline in U.S. Retail Pharmacy − Continued strong performance in International − Progress with profitability initiatives in U.S. Healthcare • Maintaining full-year 2024 adjusted EPS guidance in

  4. Slide 4: Evaluating all strategic options to improve long-term shareholder value

    Evaluating all strategic options to improve long-term shareholder value • Taking swift actions to right-size costs and increase cash flow − On pace toward $1B in cost savings, $600M in capex reduction, and $500M in working capital improvements − U.S. Healthcare on track to achieve significant year o

  5. Slide 5: Building on our core pharmacy foundation and our trusted brand

    Building on our core pharmacy foundation and our trusted brand to evolve healthcare and customer experience • Leveraging our local presence to engage with patients across our thousands of stores, and through our assets across the care continuum • Enabling pharmacists to spend less time on routine ta

  6. Slide 6: WBA 1Q24 Financial Highlights

    Reported Fx Constant Fx 1Q24 $ in millions (except EPS) B/(W) vs. 1Q23 B/(W) vs. 1Q23 Sales $36,707 + 10.0% + 8.7% Operating Income GAAP ($39) + $6,113 Adjusted $687 (32.2)% (33.0)% WBA 1Q24 Financial Net Earnings GAAP ($67) + $3,654 Highlights Adjusted $571 (43.1)% (43.7)% EPS GAAP ($0.08) + $4.23

  7. Slide 7: U.S. Retail Pharmacy Financials

    1Q24 B/(W) vs. 1Q23 $ in millions Sales $28,944 + 6.4% Adj. gross profit $5,493 (7.0)% U.S. Retail Adj. SG&A % of sales 16.9% + 1.3%p Pharmacy Adj. operating income $694 (37.2)% Financials Adj. operating margin1 2.1% (1.5)%p • Comparable sales growth of 8.1% compared to 3.8% in the prior year • Adj.

  8. Slide 8: U.S. Pharmacy

    1Q24 Total 1Q24 Comparable 1Q24 vs. 1Q23 Pharmacy sales + 10.7% + 13.1% Prescriptions 0.0% + 1.3% Prescriptions ex. Immunizations + 0.4% + 1.8% U.S. Pharmacy • Comp pharmacy sales +13.1% primarily due to brand inflation and strong execution in pharmacy services • Comp scripts +1.3%; comp scripts exc

  9. Slide 9: U.S. Retail

    1Q24 1Q24 vs. 1Q23 Total retail sales (6.1)% Comparable retail sales (5.0)% U.S. Retail • Comp retail sales (5.0)%, primarily due to macroeconomic-driven consumer trends and a weaker respiratory season, including: − 160 bps direct impact from cough cold flu, plus incremental impact from associated b

  10. Slide 10: International Financials

    Constant Fx 1Q24 $ in millions B/(W) vs. 1Q23 Sales $5,832 + 4.4% Adj. gross profit $1,211 + 7.1% Adj. SG&A % of sales 18.3% (0.3)%p International Adj. operating income $142 + 15.0% Financials Adj. operating margin 2.4% + 0.2%p • Sales increase driven by Boots UK +6.2% and Germany wholesale +3.7% •

  11. Slide 11: Boots UK Financials

    1Q24 1Q24 vs. 1Q23 Pharmacy comp. sales + 0.8% Retail comp. sales + 9.8% Boots UK • Strong retail comp sales with growth across all categories and formats Financials − +9.8% on top of +8.7% in the prior year − Store footfall ~+7% vs. prior year • Retail market share growth for the 11th consecutive q

  12. Slide 12: U.S. Healthcare Financials

    1Q24 B/(W) vs. 1Q23 $ in millions Sales $1,931 + $942 Adj. gross profit $146 + $103 Adj. SG&A $(242) $(47) U.S. Healthcare Adj. operating loss $(96) + $56 Financials Adj. EBITDA $(39) + $84 • 1Q sales led by VillageMD $1.4B, CareCentrix $340M, and Shields $133M • Pro forma sales +12%, with growth ac

  13. Slide 13: Cash Flow

    B/(W) 1Q24 $ in millions vs. 1Q23 Operating cash flow $(281) $(774) Cash capital expenditure $(506) + $104 Free cash flow $(788) $(671) Cash Flow • Operating cash flow in line with expectations, negatively impacted by anticipated inventory build ahead of the U.S. and UK holiday season and timing of

  14. Slide 14: Maintaining full-year adj. EPS guidance in a challenging environment

    Maintaining full-year adj. EPS guidance in a challenging environment • Maintaining FY24 adj. EPS of $3.20-$3.50 with 1Q in line with overall expectations • Guidance incorporates intensifying headwinds from macro-driven consumer pressures and script market softness, and strong execution in pharmacy s

  15. Slide 15: Unfavorable U.S. retail trends impacting 2Q; benefits of cost savings and U.S. Healthcare expected to scale

    Unfavorable U.S. retail trends impacting 2Q; benefits of cost savings and U.S. Healthcare expected to scale over balance of FY24 Key YOY considerations in 2Q Drivers of improving 2H earnings profile 2Q 2023 adj. EPS $1.16 • Cost savings: Benefits of recent actions to improve cost base; expected to s

  16. Slide 16: A solid start to the year, with much more to do

    A solid start to the year, with much more to do • Executing on our goals in a challenging environment • Evaluating all strategic options to improve long-term shareholder value • Building on our core pharmacy foundation and our trusted brand to evolve healthcare and customer experience • Redefining w

  17. Slide 17: Q&A

    Q&A © 2024 Walgreens Boots Alliance, Inc. All rights reserved. 17

  18. Slide 18: Endnotes

    Endnotes • Please see appendix for reconciliations of non-GAAP financial measures and related disclosures. • The Company presents certain information related to current period operating results in “constant currency,” which is a non-GAAP financial measure. These amounts are calculated by translating

  19. Slide 19: Appendix

    Appendix The information on the following pages provides reconciliations of the supplemental non-GAAP financial measures, as defined under SEC rules, presented in this presentation and discussed on the related conference call to the most directly comparable financial measures calculated and presente

  20. Slide 20: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions, except net debt ratio and lease adjusted net debt ratio) The Company defines net debt ratio as net debt divided by adjusted earnings before interest, tax,

  21. Slide 21: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) NET LOSS TO ADJUSTED OPERATING INCOME, ADJUSTED EBITDA and ADJUSTED EBITDAR As Reported Twelve months ended November 30, 2023 Net loss (GAAP) $ 9 Post-tax

  22. Slide 22: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) 1 Certain legal and regulatory accruals and settlements relate to significant charges associated with certain legal proceedings, including legal defense costs. The Compa

  23. Slide 23: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) NET LOSS TO ADJUSTED NET EARNINGS AND DILUTED NET LOSS PER SHARE Three months ended November 30, Change vs. 1Q23 TO ADJUSTED DILUTED NET EARNINGS PER SHARE

  24. Slide 24: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions, except per share amounts) NET LOSS TO ADJUSTED NET EARNINGS AND DILUTED NET LOSS PER SHARE Three months ended November 30, Change vs. 1Q23 TO ADJUSTED DILU

  25. Slide 25: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) 1 Acquisition-related amortization includes amortization of acquisition-related intangible assets, inventory valuation adjustments and stock-based compensation fair valu

  26. Slide 26: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Three months ended November 30, 2023 Walgreens Boots U.S. Retail Pharmacy1 International U.S. Healthcare Corporate and Other Alliance, Inc. Sales $ 28,944

  27. Slide 27: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Three months ended November 30, 2022 Walgreens Boots U.S. Retail Pharmacy1 International U.S. Healthcare Corporate and Other Alliance, Inc. Sales $ 27,204

  28. Slide 28: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) 1 Operating income for U.S. Retail Pharmacy includes equity earnings in Cencora. As a result of the two-month reporting lag, operating income for the three month period

  29. Slide 29: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) OPERATING LOSS TO ADJUSTED EBITDA FOR U.S. HEALTHCARE SEGMENT Three months ended November 30, 2023 2022 Operating loss (GAAP) 1 $ (436) $ (436) 2 Acquisiti

  30. Slide 30: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) EQUITY EARNINGS IN CENCORA Three months ended November 30, 2023 2022 Equity earnings in Cencora (GAAP) $ 42 $ 53 Acquisition-related intangibles amortizati

  31. Slide 31: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) ADJUSTED EFFECTIVE TAX RATE Three months ended November 30, 2023 Three months ended November 30, 2022 (Loss) Earnings Income tax (Loss) Earnings before inc

  32. Slide 32: Free Cash Flow

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) FREE CASH FLOW Three months ended November 30, 2023 2022 Net cash (used for) provided by operating activities (GAAP) $ (281) $ 493 Less: Additions to prope

  33. Slide 33: Sale-Leaseback Financial Information

    Sale-Leaseback Financial Information Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Sale-leaseback financial information Three months ended November 30, 2023 Change vs. 1Q23 U.S. Retail Pharmacy Gain on sale-leaseback 1 $ 160 $ (12) 2 Incremental s

Walgreens Boots Alliance — Q1 2024 Earnings Presentation on 6ix